Monoclonal B lymphocytosis in the general population

Antonis Dagklis, Claudia Fazi, Lydia Scarfò, Benedetta Apollonio, Paolo Ghia

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Monoclonal B lymphocytosis (MBL) is a frequent phenomenon in the general population. Despite a phenotype similar to chronic lymphocytic leukemia (CLL), the possibility exists that most cases are not necessarily a pre-leukemic condition. This is suggested by the fact that MBL is at least 100 times more frequent than CLL and the diagnosis of CLL is not an inevitable fate, even among MBL cases with lymphocytosis, where it occurs only in 1.1% of the cases per year. The high incidence of MBL, if coupled with the possibility of evolution into a frank leukemic state, poses evident clinical and health system concerns. MBL in the general population usually accounts for a very low number of all circulating B-cells, being <10% of all B lymphocytes. This creates the need for a better characterisation of MBL at molecular level, aiming to identify biological features that may define which cases are more likely to progress towards clinically overt CLL. This approach should also help to avoid unnecessary and prolonged follow-ups in all individuals carrying MBL, excluding those who are extremely unlikely to develop CLL.

Original languageEnglish
Pages (from-to)490-492
Number of pages3
JournalLeukemia and Lymphoma
Volume50
Issue number3
DOIs
Publication statusPublished - 2009

Fingerprint

Lymphocytosis
B-Cell Chronic Lymphocytic Leukemia
Population
B-Lymphocytes
Phenotype
Incidence
Health

Keywords

  • General population
  • Immunoglobulin
  • Low-count MBL
  • Monoclonal B-cell lymphocytosis

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Monoclonal B lymphocytosis in the general population. / Dagklis, Antonis; Fazi, Claudia; Scarfò, Lydia; Apollonio, Benedetta; Ghia, Paolo.

In: Leukemia and Lymphoma, Vol. 50, No. 3, 2009, p. 490-492.

Research output: Contribution to journalArticle

Dagklis, A, Fazi, C, Scarfò, L, Apollonio, B & Ghia, P 2009, 'Monoclonal B lymphocytosis in the general population', Leukemia and Lymphoma, vol. 50, no. 3, pp. 490-492. https://doi.org/10.1080/10428190902763475
Dagklis, Antonis ; Fazi, Claudia ; Scarfò, Lydia ; Apollonio, Benedetta ; Ghia, Paolo. / Monoclonal B lymphocytosis in the general population. In: Leukemia and Lymphoma. 2009 ; Vol. 50, No. 3. pp. 490-492.
@article{534e5da2b49d4c4c847b183fb5f5d196,
title = "Monoclonal B lymphocytosis in the general population",
abstract = "Monoclonal B lymphocytosis (MBL) is a frequent phenomenon in the general population. Despite a phenotype similar to chronic lymphocytic leukemia (CLL), the possibility exists that most cases are not necessarily a pre-leukemic condition. This is suggested by the fact that MBL is at least 100 times more frequent than CLL and the diagnosis of CLL is not an inevitable fate, even among MBL cases with lymphocytosis, where it occurs only in 1.1{\%} of the cases per year. The high incidence of MBL, if coupled with the possibility of evolution into a frank leukemic state, poses evident clinical and health system concerns. MBL in the general population usually accounts for a very low number of all circulating B-cells, being <10{\%} of all B lymphocytes. This creates the need for a better characterisation of MBL at molecular level, aiming to identify biological features that may define which cases are more likely to progress towards clinically overt CLL. This approach should also help to avoid unnecessary and prolonged follow-ups in all individuals carrying MBL, excluding those who are extremely unlikely to develop CLL.",
keywords = "General population, Immunoglobulin, Low-count MBL, Monoclonal B-cell lymphocytosis",
author = "Antonis Dagklis and Claudia Fazi and Lydia Scarf{\`o} and Benedetta Apollonio and Paolo Ghia",
year = "2009",
doi = "10.1080/10428190902763475",
language = "English",
volume = "50",
pages = "490--492",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "3",

}

TY - JOUR

T1 - Monoclonal B lymphocytosis in the general population

AU - Dagklis, Antonis

AU - Fazi, Claudia

AU - Scarfò, Lydia

AU - Apollonio, Benedetta

AU - Ghia, Paolo

PY - 2009

Y1 - 2009

N2 - Monoclonal B lymphocytosis (MBL) is a frequent phenomenon in the general population. Despite a phenotype similar to chronic lymphocytic leukemia (CLL), the possibility exists that most cases are not necessarily a pre-leukemic condition. This is suggested by the fact that MBL is at least 100 times more frequent than CLL and the diagnosis of CLL is not an inevitable fate, even among MBL cases with lymphocytosis, where it occurs only in 1.1% of the cases per year. The high incidence of MBL, if coupled with the possibility of evolution into a frank leukemic state, poses evident clinical and health system concerns. MBL in the general population usually accounts for a very low number of all circulating B-cells, being <10% of all B lymphocytes. This creates the need for a better characterisation of MBL at molecular level, aiming to identify biological features that may define which cases are more likely to progress towards clinically overt CLL. This approach should also help to avoid unnecessary and prolonged follow-ups in all individuals carrying MBL, excluding those who are extremely unlikely to develop CLL.

AB - Monoclonal B lymphocytosis (MBL) is a frequent phenomenon in the general population. Despite a phenotype similar to chronic lymphocytic leukemia (CLL), the possibility exists that most cases are not necessarily a pre-leukemic condition. This is suggested by the fact that MBL is at least 100 times more frequent than CLL and the diagnosis of CLL is not an inevitable fate, even among MBL cases with lymphocytosis, where it occurs only in 1.1% of the cases per year. The high incidence of MBL, if coupled with the possibility of evolution into a frank leukemic state, poses evident clinical and health system concerns. MBL in the general population usually accounts for a very low number of all circulating B-cells, being <10% of all B lymphocytes. This creates the need for a better characterisation of MBL at molecular level, aiming to identify biological features that may define which cases are more likely to progress towards clinically overt CLL. This approach should also help to avoid unnecessary and prolonged follow-ups in all individuals carrying MBL, excluding those who are extremely unlikely to develop CLL.

KW - General population

KW - Immunoglobulin

KW - Low-count MBL

KW - Monoclonal B-cell lymphocytosis

UR - http://www.scopus.com/inward/record.url?scp=67650922158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650922158&partnerID=8YFLogxK

U2 - 10.1080/10428190902763475

DO - 10.1080/10428190902763475

M3 - Article

VL - 50

SP - 490

EP - 492

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -